Quotes 5-day view Delayed Nasdaq
10/19/2020
10/20/2020
10/21/2020
10/22/2020
10/23/2020
Date
28.16(c)
27.57(c)
27.5(c)
28.81(c)
28.105(c)
Last
353 538
299 866
131 903
223 390
304 440
Volume
-2.90% -2.10% -0.25% +4.76% -2.45% Change
Sales 2020
-
-
-
Net income 2020
-105 M - -
Net cash position 2020
286 M - -
P/E ratio 2020
-15,4x
Yield 2020
-
Sales 2021
9,30 M - -
Net income 2021
-130 M - -
Net cash position 2021
300 M - -
P/E ratio 2021
-13,4x
Yield 2021
-
Capitalization
1 590 M 1 590 M -
EV / Sales 2020
-
EV / Sales 2021
139x
Nbr of Employees
79
Free-Float
91,0%
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the...
Notations Surperformance© of Rocket Pharmaceuticals, Inc.
Trading Rating : Investor Rating : -
All news about ROCKET PHARMACEUTICALS, INC.
News in other languages on ROCKET PHARMACEUTICALS, INC.
- No features available -
Chart ROCKET PHARMACEUTICALS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
12
Average target price
36,90 $
Last Close Price
28,81 $
Spread / Highest target
63,1%
Spread / Average Target
28,1%
Spread / Lowest Target
7,60%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
